A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (E1303)

Cancer

Volumn 117, Issue 15, 2011, Pages 3374-3382

  Argiris, Athanassios ^a   Ghebremichael, Musie ^b   Burtness, Barbara ^c   Axelrod, Rita S ^d   Deconti, Ronald C ^e   Forastiere, Arlene A ^f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenoid cystic carcinoma; bortezomib; doxorubicin; head and neck cancer

Indexed keywords

BORTEZOMIB; DOXORUBICIN;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER GROWTH; CANCER PAIN; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FLUSHING; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RECURRENT CANCER; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STOMATITIS; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARCINOMA, ADENOID CYSTIC; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 79960698423     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25852     Document Type: Article

References (29)

1. Jones AS, Hamilton JW, Rowley H, Husband D, Helliwell TR,. Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol Allied Sci. 1997; 22: 434-443. (Pubitemid 28344903)
2. Spiro RH,. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997; 174: 495-498. (Pubitemid 127738601)
3. Laurie SA, Licitra L,. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006; 24: 2673-2678. (Pubitemid 46622089)
4. Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1993; 4: 785-788. (Pubitemid 23340091)
5. Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1996; 7: 867-869. (Pubitemid 26345882)
6. Tannock IF, Sutherland DJ,. Chemotherapy for adenocystic carcinoma. Cancer. 1980; 46: 452-454. (Pubitemid 10036634)
7. Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D,. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987; 60: 2869-2872. (Pubitemid 18005856)
8. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996; 7: 640-642. (Pubitemid 26285647)
9. Airoldi M, Bumma C, Bertetto O, Gabriele P, Succo G, Pedani F,. Vinorelbine treatment of recurrent salivary gland carcinomas. Bull Cancer. 1998; 85: 892-894. (Pubitemid 28530075)
10. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001; 91: 541-547. (Pubitemid 32105699)
11. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006; 28: 197-204. (Pubitemid 43269885)
12. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J,. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999; 5: 2638-2645. (Pubitemid 29437352)
13. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9: 1136-1144. (Pubitemid 36323723)
14. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101: 2377-2380. (Pubitemid 36302084)
15. LoConte NK, Thomas JP, Alberti D, et al. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2008; 63: 109-115.
16. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol. 2008; 19: 1160-1165. (Pubitemid 351796343)
17. Zhang J, Peng B,. NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. Cell Prolif. 2009; 42: 150-161.
18. Zhang J, Peng B, Chen X,. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 2005; 11: 7334-7343. (Pubitemid 41507692)
19. Azuma M, Motegi K, Aota K, Yamashita T, Yoshida H, Sato M,. TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1. Exp Cell Res. 1999; 250: 213-222. (Pubitemid 29391585)
20. Motegi K, Azuma M, Aota K, et al. Effect of a mutant form of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed human salivary gland cells. Oral Oncol. 2001; 37: 185-192. (Pubitemid 32146666)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
22. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
23. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M,. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007; 43: 33-36. (Pubitemid 46162246)
24. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005; 23: 585-590. (Pubitemid 46224236)
25. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007; 25: 3978-3984. (Pubitemid 47477277)
26. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003; 39: 724-727. (Pubitemid 36930120)
27. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M,. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol. 2005; 23 (16 suppl pt 1): 5532.
28. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009; 45: 574-578.
29. Kotsakis T, Gooding WE, Argiris A,. Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable adenoid cystic carcinoma of the head and neck. J Clin Oncol. 2010; 28 (15 suppl). Abstract TPS271.